With the development and commercialization of immunotherapy drugs such as checkpoint inhibitors, the field of immuno-oncology is transforming the treatment of patients with cancer. However, cures remain elusive, and many cancer patients experience only modest clinical benefit.

Neoantigens represent a novel class of targets for advancing cancer immunotherapy and have been validated in cancer patients as critical T cell targets. However, the identification of neoantigens presents a key therapeutic challenge.

Neoantigens can be classified as either individualized, meaning each patient has their own unique neoantigens, or shared, in which common driver mutations are found across some patients.